Short answer
STANDARD BIOTOOLS INC. (LAB) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $19M (down 0.9% year over year) with net income of $13M.
Q3 2026 key financials · XBRL
- Revenue
- $19M
- −0.9% YoY · −3.6% QoQ
- Net income
- $13M
- +138.9% YoY · +150.4% QoQ
- Operating margin
- -102.0%
- Gross margin
- 55.9%
- EPS (diluted)
- $0.03
- +133.3% YoY · +142.9% QoQ
Source: XBRL data from the STANDARD BIOTOOLS INC. (LAB) Q3 2026 10-Q on SEC EDGAR. USD.
STANDARD BIOTOOLS INC. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $19.385M, down $0.167M or 1% YoY, with instruments up 18% to $5.998M
- Gross margin 55.9% vs 48.5% YoY, gross profit $10.828M vs $9.484M
- Services and other revenue weakest line, down 12% to $5.057M; consumables down 4% to $8.330M
- Cash, cash equivalents and investments $559.4M vs $213.3M at December 31, 2025; operating cash use $63.1M
- Merger expected in fourth quarter of 2026; liquidity expected sufficient for at least the next 12 months
Risk Factors
- Merger agreement risk: representations and warranties expire at Closing, eliminating post-closing indemnification for undisclosed liabilities
- Legal risk: July and August 2026 stockholder demands could delay or enjoin the Merger
- CVR monetization risk: no payments if legacy-business proceeds, investment proceeds, contingent payments, and Parent Net Cash surplus are absent
- Dilution risk: CVR settlements may issue up to 76,000,000 combined-company shares
- Liquidity risk: unsecured CVRs are subordinated to senior obligations and lack an established trading market
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other STANDARD BIOTOOLS INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.